July 29 (Reuters) - AstraZeneca ( AZN ) beat
second-quarter earnings expectations on Tuesday, helped by
strong sales of key cancer, heart and kidney disease drugs, but
maintained its full-year forecast as pricing pressures and
global trade risks remain challenges.
(Reporting by Pushkala Aripaka and Unnamalai L in Bengaluru,
and Maggie Fick in London; Editing by Subhranshu Sahu)